Loading...
XASXIVX
Market cap11mUSD
Jan 07, Last price  
0.26AUD
1D
0.00%
1Q
8,733.33%
Jan 2017
16,682.77%
IPO
-21.60%
Name

Invion Ltd

Chart & Performance

D1W1MN
XASX:IVX chart
P/E
—
P/S
4.92
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
3.17%
Rev. gr., 5y
-0.99%
Revenues
4m
-10.00%
00000207,337185,355139,1000737,7133,882,0963,476,7842,330,0273,291,7634,104,7113,694,256
Net income
-6m
L+248.51%
0-16,787,189-13,679,994-5,540,923-5,174,080-6,883,937-13,041,233-4,447,709-2,199,737-926,507-2,546,205-953,894-1,482,951-2,241,379-1,614,823-5,627,765
CFO
-2m
L+32.47%
00-13,456,1110-3,458,561-4,353,923-10,131,201-3,832,164-247,139707,087-2,105,693-152,470417,975-1,108,901-1,812,704-2,401,377
Earnings
Feb 26, 2025

Profile

Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.
URL
https://inviongroup.com/
IPO date
Feb 15, 2010
Employees
8
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
3,694
-10.00%
4,105
24.70%
3,292
41.28%
Cost of revenue
11,422
7,968
7,513
Unusual Expense (Income)
NOPBT
(7,727)
(3,864)
(4,222)
NOPBT Margin
Operating Taxes
3
194
Tax Rate
NOPAT
(7,727)
(3,864)
(4,416)
Net income
(5,628)
248.51%
(1,615)
-27.95%
(2,241)
51.14%
Dividends
Dividend yield
Proceeds from repurchase of equity
15,796
14,954
BB yield
-61.51%
-27.16%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(784)
(4,085)
(8,473)
Cash flow
Cash from operating activities
(2,401)
(1,813)
(1,109)
CAPEX
(2,576)
(7,250)
Cash from investing activities
(900)
(2,576)
(7,250)
Cash from financing activities
15,796
15,796
FCF
(7,027)
(4,887)
(4,415)
Balance
Cash
784
4,085
8,473
Long term investments
Excess cash
599
3,880
8,309
Stockholders' equity
14,438
18,396
19,579
Invested Capital
13,839
14,517
11,270
ROIC
ROCE
EV
Common stock shares outstanding
6,424,407
6,419,595
6,117,403
Price
0.00
0.00%
0.00
-55.56%
0.01
-30.77%
Market cap
25,698
0.07%
25,678
-53.36%
55,057
-23.36%
EV
24,914
21,593
46,583
EBITDA
(6,911)
(3,180)
(3,799)
EV/EBITDA
Interest
240
Interest/NOPBT